logo-loader
viewBoeing Co

Boeing shares fly a little higher after three days of test flights for its 737 MAX

The Max has been grounded since March last year after two horror crashes within five months of each other

Boeing Co -
The Federal Aviation Administration and Boeing have completed the required re-certification flight tests on the 737 MAX

Boeing (NYSE:BA) shares flew a little higher on Thursday as the airplane giant moved a little closer to getting its 737 Max jets off the ground.

The Max has been grounded since March last year after two horror crashes within five months of each other, which killed 346 people.

READ: Boeing posts net loss for second straight quarter, unveils plans to cut its workforce by about 10%

US regulator Federal Aviation Administration (FAA) and Boeing have on Wednesday completed the required re-certification flight tests on the 737 MAX, moving it closer to FAA approval to return to service.

During three days of testing, FAA pilots and engineers reportedly evaluated Boeing’s proposed changes to the automated flight control system, which was implicated in the two crashes.

"The agency is following a deliberate process and will take the time it needs to thoroughly review Boeing’s work," the FAA said Thursday. "We will lift the grounding order only after FAA safety experts are satisfied that the aircraft meets certification standards."

Boeing shares gained 0.67% on Wall Street to stand at US$181.53 each.

In London, the stock ticked up 0.11% to stand at 181.24p.

Quick facts: Boeing Co

Price: 174.28 USD

NYSE:BA
Market: NYSE
Market Cap: $98.37 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Amryt Pharma releases Q-2 financials that show strong revenue growth as...

Amryt Pharma (Nasdaq: AMYT) CEO Dr Joe Wiley joined Steve Darling from Proactive with news the company saw a nice increase in revenue as they released their Q-2 numbers. Dr Wiley talked about some of the numbers and what was driving that revenue. Wiley also told Proactive the company has, for...

31 minutes ago

2 min read